help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

Journal of Clinical Endocrinology & Metabolism , doi:10.1210/jc.2007-2803
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Visekruna, M.
Right arrow Articles by McKiernan, F. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Visekruna, M.
Right arrow Articles by McKiernan, F. E.
Related Collections
Right arrow Calcium and Bone Metabolism
Right arrow Female Endocrinology
The Journal of Clinical Endocrinology & Metabolism Vol. 93, No. 8 2948-2952
Copyright © 2008 by The Endocrine Society


CLINICAL CASE SEMINAR

Severely Suppressed Bone Turnover and Atypical Skeletal Fragility

Maja Visekruna, Deborah Wilson and Fergus Eoin McKiernan

Center for Bone Disease, Marshfield Clinic, Marshfield, Wisconsin 54449

Address all correspondence and requests for reprints to: Maja Visekruna, M.D., Marshfield Clinic, 1000 North Oak Avenue, Marshfield, Wisconsin 54449. E-mail: visekruna.maja{at}marshfieldclinic.org.

Context: Since their introduction into clinical medicine, bisphosphonates have revolutionized clinical osteoporosis care. Ironically, in rare circumstances, long-term, combined anti-remodeling therapy may be associated with skeletal harm.

Evidence Acquisition: We report atypical skeletal fragility in three subjects after long-term, combined anti-remodeling therapy.

Evidence Synthesis: Three subjects experienced spontaneous or minimal-trauma chalk-stick type metadiaphyseal femoral fractures while on long-term bisphosphonate therapy. The fracture location, type, bilaterality, prodromal pain, and delayed healing were atypical for uncomplicated postmenopausal osteoporosis. All three subjects had concomitant circumstances (endogenous estrogen) or medications (glucocorticoids, hormone replacement therapy, and raloxifene) that likely suppressed bone remodeling beyond the effect of the bisphosphonate alone. Biochemical markers of bone turnover were very low or in the low premenopausal range. Double tetracycline-labeled bone biopsy showed very low activation frequency in one subject and limited single tetracycline label in a second consistent with severely suppressed bone turnover (SSBT). These three cases resemble previous descriptions of SSBT.

Conclusion: Atypical skeletal fragility may signify SSBT in the setting of long-term, combined anti-remodeling therapy. We speculate that osteoclast tolerance for pharmacological suppression may vary among individual patients and that in some cases combined anti-remodeling therapy may result in skeletal harm.




This article has been cited by other articles:


Home page
IBMS BoneKEyHome page
N. A. Andrews
Postoperative Management of Hip Fractures: Recent inaugural IBMS BoneKEy Online Forum focused on pharmacological and non-pharmacological approaches to managing patients post-hip fracture
IBMS BoneKEy, February 1, 2009; 6(2): 55 - 62.
[Full Text] [PDF]


Home page
J Am Acad Orthop SurgHome page
M. J. Silva, D. B. Burr, F. R. T. Nelson, and M. Flynn
On the Horizon From the ORS
J. Am. Acad. Ortho. Surg., January 1, 2009; 17(1): 56 - 59.
[Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2008 by The Endocrine Society